References
- Ferlay JEM, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. International Agency for Research on Cancer; 2020. Available from: https://gco.iarc.fr/today.
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–1 10. doi:https://doi.org/10.1158/0008-5472.CAN-14-0155.
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1 10. doi:https://doi.org/10.1056/NEJMoa1304369.
- Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1 10. doi:https://doi.org/10.1056/NEJMoa1011923.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:https://doi.org/10.3322/caac.21387.
- Mangiavillano B, Sosa-Valencia L, Deprez P, Eisendrath P, Robles-Medranda C, Eusebi LH, et al. Tissue acquisition and pancreatic masses: which needle and which acquisition technique should be used? Endosc Int Open. 2020;8(10):E1315–E1320. doi:https://doi.org/10.1055/a-1221-4578.
- Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93(1):136–1 10. doi:https://doi.org/10.1073/pnas.93.1.136.
- Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27(11):1418–1 10. doi:https://doi.org/10.1097/00000478-200311000-00003.
- Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7(12):3862–1 10.
- Thomas A, Chen Y, Steinberg SM, Luo J, Pack S, Raffeld M, et al. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget. 2015;6(13):11694–1 10. doi:https://doi.org/10.18632/oncotarget.3429.
- Nomura R, Fujii H, Abe M, Sugo H, Ishizaki Y, Kawasaki S, et al. Mesothelin expression is a prognostic factor in cholangiocellular carcinoma. Int Surg. 2013;98(2):164–1 10. doi:https://doi.org/10.9738/INTSURG-D-13-00001.1.
- Li YR, Xian RR, Ziober A, Conejo-Garcia J, Perales-Puchalt A, June CH, et al. Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Res Treat. 2014;147(3):675–1 10. doi:https://doi.org/10.1007/s10549-014-3077-5.
- Dainty LA, Risinger JI, Morrison C, Chandramouli GVR, Bidus MA, Zahn C, et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol. 2007;105(3):563–1 10. doi:https://doi.org/10.1016/j.ygyno.2006.10.063.
- Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, Hassan R, et al. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. Eur J Haematol. 2007;79(4):281–1 10. doi:https://doi.org/10.1111/j.1600-0609.2007.00928.x.
- Gubbels JAA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5(1):50. doi:https://doi.org/10.1186/1476-4598-5-50.
- Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem. 2009;284(6):3739–1 10. doi:https://doi.org/10.1074/jbc.M806776200.
- Avula LR, Rudloff M, El-Behaedi S, Arons D, Albalawy R, Chen X, et al. Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases. Mol Cancer Res. 2020;18(2):229–1 10. doi:https://doi.org/10.1158/1541-7786.MCR-19-0688.
- Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, et al. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J. 2009;424(3):449–1 10. doi:https://doi.org/10.1042/BJ20082196.
- Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 2011;10:106. doi:https://doi.org/10.1186/1476-4598-10-106.
- Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, Mao TL, et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J. 2012;442(2):293–302. doi:https://doi.org/10.1042/BJ20110282.
- Uehara N, Matsuoka Y, Tsubura A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res. 2008;6(2):186–1 10. doi:https://doi.org/10.1158/1541-7786.MCR-07-0254.
- Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J-i, Sima C, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012;18(9):2478–1 10. doi:https://doi.org/10.1158/1078-0432.CCR-11-2614.
- He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, et al. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer. 2017;16(1):63. doi:https://doi.org/10.1186/s12943-017-0633-8.
- Zheng C, Jia W, Tang Y, Zhao H, Jiang Y, Sun S, et al. Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway. J Exp Clin Cancer Res. 2012;31:84. doi:https://doi.org/10.1186/1756-9966-31-84.
- Wang Y, Wang L, Li D, Wang HB, Chen QF. Mesothelin promotes invasion and metastasis in breast cancer cells. J Int Med Res. 2012;40(6):2109–1 10. doi:https://doi.org/10.1177/030006051204000608.
- Mizukami T, Kamachi H, Fujii Y, Matsuzawa F, Einama T, Kawamata F, et al. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model. Oncotarget. 2018;9(73):33844–1 10. doi:https://doi.org/10.18632/oncotarget.26117.
- Lazzerini L, Jöhrens K, Sehouli J, Cichon G. Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells. Arch Gynecol Obstet. 2020;302(5):1255–1 10. doi:https://doi.org/10.1007/s00404-020-05734-9.
- Terwisscha van Scheltinga AGT, Ogasawara A, Pacheco G, Vanderbilt AN, Tinianow JN, Gupta N, et al. Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative 89Zr-immunoPET. Mol Cancer Ther. 2017;16(1):134–1 10. doi:https://doi.org/10.1158/1535-7163.MCT-16-0449.
- Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, et al. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. Mol Oncol. 2016;10(8):1317–1 10. doi:https://doi.org/10.1016/j.molonc.2016.07.003.
- Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, et al. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer. 2010;1:141–1 10. doi:https://doi.org/10.7150/jca.1.141.
- Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther. 2014;13(11):2630–1 10. doi:https://doi.org/10.1158/1535-7163.MCT-14-0487-T.
- Kim H, Gao W, Ho M. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. PLoS One. 2013;8(11):e81919. doi:https://doi.org/10.1371/journal.pone.0081919.
- Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012;20(3):633–1 10. doi:https://doi.org/10.1038/mt.2011.256.
- Hassan R, Blumenschein GR, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol. 2020;38(16):1824–1 10. doi:https://doi.org/10.1200/JCO.19.02085.
- Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927–1 10. doi:https://doi.org/10.1158/1078-0432.CCR-14-0804.
- Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27(11):1919–1 10. doi:https://doi.org/10.1016/j.ymthe.2019.07.015.
- Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, et al. Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res. 2019;25(19):5787–1 10. doi:https://doi.org/10.1158/1078-0432.CCR-19-0070.
- Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, et al. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther. 2016;15(3):439–447. doi:https://doi.org/10.1158/1535-7163.MCT-15-0693.
- Jiang Q, Ghafoor A, Mian I, Rathkey D, Thomas A, Alewine C, et al. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci Transl Med. 2020;12(550):eaaz7252. doi:https://doi.org/10.1126/scitranslmed.aaz7252.
- Gnemmi V, Leroy X, Triboulet JP, Pruvot FR, Villers A, Leteurtre E, et al. Pancreatic metastases of renal clear cell carcinoma: a clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas. Anal Quant Cytopathol Histpathol. 2013;35(3):157–1 10.
- Nahm CB, Turchini J, Jamieson N, Moon E, Sioson L, Itchins M, et al. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study. Eur J Surg Oncol. 2019;45(2):218–224. doi:https://doi.org/10.1016/j.ejso.2018.10.050.
- Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, et al. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011;40(8):1276–1 10. doi:https://doi.org/10.1097/MPA.0b013e318221bed8.
- Le K, Wang J, Zhang T, Guo Y, Chang H, Wang S, et al. Overexpression of mesothelin in pancreatic ductal adenocarcinoma (PDAC). Int J Med Sci. 2020;17(4):422–1 10. doi:https://doi.org/10.7150/ijms.39012.
- Meng Q, Liu Z, Rangelova E, Poiret T, Ambati A, Rane L, et al. Expansion of tumor-reactive T cells from patients with pancreatic cancer. J Immunother. 2016;39(2):81–1 10. doi:https://doi.org/10.1097/CJI.0000000000000111.
- Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S, et al. Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. PLoS One. 2014;9(2):e88133. doi:https://doi.org/10.1371/journal.pone.0088133.
- Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–1 10. doi:https://doi.org/10.1038/nm0798-844.
- Fraune C, Burandt E, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, et al. MMR deficiency is homogeneous in pancreatic carcinoma and associated with high density of Cd8-positive lymphocytes. Ann Surg Oncol. 2020;27(10):3997–4006. doi:https://doi.org/10.1245/s10434-020-08209-y.
- Blessin NC, Li W, Mandelkow T, Jansen HL, Yang C, Raedler JB, et al. Prognostic role of proliferating CD8+ cytotoxic T-cells in human cancers. Cell Oncol (Dord). 2021. doi: https://doi.org/10.1007/s13402-021-00601-4.
- Inaguma S, Wang Z, Lasota J, Onda M, Czapiewski P, Langfort R, et al. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. Oncotarget. 2017;8(16):26744–1 10. doi:https://doi.org/10.18632/oncotarget.15814.
- Illei PB, Alewine C, Zahurak M, Cowan ML, Montgomery E, Hassan R, et al. Mesothelin expression in advanced gastroesophageal cancer represents a novel target for immunotherapy. Appl Immunohistochem Mol Morphol. 2016;24(4):246–1 10. doi:https://doi.org/10.1097/PAI.0000000000000292.
- Ibrahim DA, Abouhashem NS. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis. Pathol Res Pract. 2016;212(4):288–1 10. doi:https://doi.org/10.1016/j.prp.2016.01.007.
- Glass JP, Parasher G, Arias-Pulido H, Donohue R, Prossnitz ER, Cerilli LA, et al. Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms. Int J Surg Pathol. 2011;19(5):588–1 10. doi:https://doi.org/10.1177/1066896911409575.
- Baruch AC, Wang H, Staerkel GA, Evans DB, Hwang RF, Krishnamurthy S, et al. Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol. 2007;35(3):143–1 10. doi:https://doi.org/10.1002/dc.20594.
- Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol. 2005;29(3):381–1 10. doi:https://doi.org/10.1097/01.pas.0000149710.01559.fe.
- Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 2005;24(1):67–72.
- Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35(3):357–1 10. doi:https://doi.org/10.1016/j.humpath.2003.10.012.
- McCarthy DM, Maitra A, Argani P, Rader AE, Faigel DO, Van Heek NT, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol. 2003;11(3):238–1 10. doi:https://doi.org/10.1097/00129039-200309000-00006.
- Frierson HF, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Jr, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34(6):605–1 10. doi:https://doi.org/10.1016/S0046-8177(03)00177-1.
- Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16(3):192–1 10. doi:https://doi.org/10.1097/01.MP.0000056981.16578.C3.
- Basturk O, Chung SM, Hruban RH, Adsay NV, Askan G, Iacobuzio-Donahue C, et al. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch. 2016;469(5):523–1 10. doi:https://doi.org/10.1007/s00428-016-2014-x.
- Frank R, Li S, Ahmad NA, Sepulveda AR, Jhala NC. Mesothelin expression in pancreatic mucinous cysts. Am J Clin Pathol. 2014;142(3):313–1 10. doi:https://doi.org/10.1309/AJCPDTTL2I5ECMFG.
- Jhala N, Jhala D, Vickers SM, Eltoum I, Batra SK, Manne U, et al. Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol. 2006;126(4):572–1 10. doi:https://doi.org/10.1309/CEV30BE088CBDQD9.
- Dim DC, Jiang F, Qiu Q, Li T, Darwin P, Rodgers WH, et al. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn Cytopathol. 2014; 42(3):193–1 10. doi:https://doi.org/10.1002/dc.21684.
- Showalter SL, Huang YH, Witkiewicz A, Costantino CL, Yeo CJ, Green JJ, et al. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther. 2008;7(10):1584–1 10. doi:https://doi.org/10.4161/cbt.7.10.6562.
- Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124(6):838–1 10. doi:https://doi.org/10.1309/F1B64CL7H8VJKEAF.
- Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16(9):902–1 10. doi:https://doi.org/10.1097/01.MP.0000086072.56290.FB.
- Van Heek NT, Maitra A, Koopmann J, Fedarko N, Jain A, Rahman A, et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther. 2004;3(7):651–656. doi:https://doi.org/10.4161/cbt.3.7.919.
- Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11(10):3766–1 10. doi:https://doi.org/10.1158/1078-0432.CCR-04-2236.
- Bharadwaj U, Li M, Chen C, Yao Q. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res. 2008;6(11):1755–1 10. doi:https://doi.org/10.1158/1541-7786.MCR-08-0095.
- Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis. 2011;32(7):1013–1 10. doi:https://doi.org/10.1093/carcin/bgr075.,
- Shen J, Sun X, Zhou J. Insights into the role of mesothelin as a diagnostic and therapeutic target in ovarian carcinoma. Front Oncol. 2020;10:1263. doi:https://doi.org/10.3389/fonc.2020.01263.
- Inoue S, Tsunoda T, Riku M, Ito H, Inoko A, Murakami H, et al. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncol Lett. 2020;19(3):1741–1 10. doi:https://doi.org/10.3892/ol.2020.11290.
- Hanaoka T, Hasegawa K, Kato T, Sato S, Kurosaki A, Miyara A, et al. Correlation between tumor mesothelin expression and serum mesothelin in patients with epithelial ovarian carcinoma: a potential noninvasive biomarker for Mesothelin-targeted therapy. Mol Diagn Ther. 2017;21(2):187–1 10. doi:https://doi.org/10.1007/s40291-017-0255-2.
- Duan X, Zhao L, Dong H, Zhao W, Liu S, Sui G, et al. Microfluidic immunoassay system for rapid detection and semi-quantitative determination of a potential serum biomarker mesothelin. ACS Sens. 2019;4(11):2952–1 10. doi:https://doi.org/10.1021/acssensors.9b01430.
- Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, et al. ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment. Clin Cancer Res. 2016;22(7):1642–1 10. doi:https://doi.org/10.1158/1078-0432.CCR-15-1272.